MUDr. Ester Mejstříková, Ph.D.
| Address: | V Úvalu 84, Praha 5 - Motol |
|---|---|
| Office: | Klinika dětské hematologie a onkologie |
| Fax: | |
| Additional information: | https://is.cuni.cz/webapps/whois/osoba/?entId=722412 |
| Faculty: | Faculty of Science |
| Department: | Department of Cell Biology (31-151) |
| Phone: | 224436477 |
| E-mail: | ester.mejstrikova@natur.cuni.cz |
| Consultation hours: | |
| Courses Schedule Opinion survey results Announced theses Supervised theses | |
| Faculty: | Second Faculty of Medicine |
| Department: | Department of Paediatric Haematology and Oncology (13-462) |
| Phone: | 224436477 |
| E-mail: | ester.mejstrikova@lfmotol.cuni.cz |
| Courses Schedule Noticeboard |
| Currently supervised PhD students | |||||||||||||||||||
  Doctoral student |  Faculty | Study programme | Branch of study | Student since | Status of studies | Dissertation | |||||||||||||
hidden | 2.LF | Immunology | Immunology | 2023 | studying | Minimal residual disease monitoring and composition of non-malignant subsets during the therapy of pediatric hematological malignancies | |||||||||||||
| Previously supervised PhD students | |||||||||||||||||||
| Doctoral student | Faculty | Study programme | Branch of study | Student since | Year of completion | Status of studies | Dissertation | Supervisor from | Supervisor until | Current supervisor | |||||||||
| hidden | 2.LF | Immunology | Immunology | 2011 | 2016 | graduated | Immunopathological mechanisms of bone marrow failure | 12.09.2011 | 26.09.2017 | ||||||||||
| hidden | 2.LF | Molecular and Cell Biology, Genetics and Virology | Molecular and Cell Biology, Genetics and Virology | 2009 | 2014 | graduated | Lineage plasticity of leukemic cells | 02.10.2012 | 16.12.2014 | ||||||||||
| hidden | 2.LF | Immunology | Immunology | 2017 | 2021 | graduated | Lineage plasticity of leukemic blasts. Importance for detection of minimal residual disease and study of hematopoesis | 20.09.2017 | 20.09.2022 | ||||||||||
| Announced topics | |||||||||||||||||||
| Dissertation | Faculty | ||||||||||||||||||
| Minimal residual disease monitoring and composition of non malignant subsets during the therapy of acute leukemias | 2.LF | ||||||||||||||||||